Raphamin
Sponsors
Materia Medica Holding
Conditions
Acute BronchitisAcute Respiratory Viral InfectionBronchitisCommunity-acquired PneumoniaCoronavirus Disease 2019 (COVID-19)Cystitis BacterialCystitis ChronicPneumonia
Phase 3
Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old
CompletedNCT04918771
Start: 2021-04-29End: 2023-07-21Updated: 2024-10-15
Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
CompletedNCT05364671
Start: 2022-04-29End: 2023-08-18Updated: 2025-01-06
Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
CompletedNCT06263881
Start: 2023-12-01End: 2025-03-19Updated: 2025-04-04
Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis
Active, not recruitingNCT06284265
Start: 2023-10-16End: 2026-12-31Updated: 2026-02-13
Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years
RecruitingNCT06715891
Start: 2024-11-11End: 2027-12-31Target: 374Updated: 2026-03-13
The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
RecruitingNCT06901297
Start: 2025-04-03End: 2027-12-31Target: 552Updated: 2026-03-16
Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients
RecruitingNCT07650227
Start: 2025-12-09End: 2028-12-31Target: 308Updated: 2026-06-29